A pioneering medical trial has discovered that administering stem cells to fetuses suffering from spina bifida as part of a surgical repair can be a "significant breakthrough" in treating birth defects.
Trial Details and Safety
The US-based trial involved six unborn babies with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells on the exposed area of the baby's spinal cord while the defect was being closed.
Importantly, the stem cell application demonstrated a favorable safety profile. Doctors verified that the cells did not cause neoplasms, hinder surgical recovery, or impede the resolution of related neurological issues.
Promising Outcomes
Magnetic resonance imaging performed on the newborns confirmed a complete reversal of hindbrain herniation in each of the babies. This favorable anatomical change is strongly associated with better mobility and function.
"If it makes more children capable of walking who wouldn't have, it may emerge as their standard of care," commented the principal investigator. "These findings are extremely promising and open the door to a variety of prospective new treatments."
Long-Term Prospects and Optimism
Experts not involved in the trial have suggested that additional validation of these noted improvements could signal a "new era" in in-utero treatment. The potential to improve nerve function impairment seen in utero is regarded as a paradigm-shifting aim.
Notably important would be improvements in bladder and bowel function, which are frequent complications for individuals living with this defect.
Looking Ahead
Despite this being a first-in-human effort focused on a handful of cases, its established security and encouraging indicators provide a strong foundation for larger, more comprehensive studies. The combination of regenerative medicine with current in-utero repair procedures offers substantial hope for improving the prognosis for infants diagnosed prenatally with myelomeningocele.